{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:08:59Z","timestamp":1779253739892,"version":"3.51.4"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pregnancy-associated breast cancer in patients with hereditary breast and ovarian cancer syndrome (HBOC) is relatively rare, and reports on treatment outcomes, including those involving risk-reducing surgery, remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 38-year-old woman at 8 weeks\u2019 gestation presented with a palpable mass in the left breast. Imaging revealed a tumor in the left breast, and further evaluation led to a diagnosis of luminal B-like, stage IIA left breast cancer. Her family history included a paternal cousin with pregnancy-associated breast cancer at age 37, a maternal grandmother with ovarian cancer at age 68, and a maternal grandaunt with breast cancer.\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      genetic testing identified a pathogenic variant in\n                      <jats:italic>BRCA1<\/jats:italic>\n                      . The patient had previously lost her fourth child due to a fetal anomaly (anencephaly) during pregnancy and strongly wished to continue her current pregnancy with her fifth child. Given that neoadjuvant chemotherapy would not affect the surgical approach, that only anthracycline-based therapy can be administered during pregnancy, and that postoperative adjuvant therapy would not be significantly impacted, as well as the potential fetal risks associated with prolonged general anesthesia, contralateral risk-reducing mastectomy (CRRM) was deferred until after delivery. Left total mastectomy with sentinel lymph node biopsy was performed first. As postoperative adjuvant therapy, she received four cycles of doxorubicin and cyclophosphamide during pregnancy, followed by four cycles of docetaxel after delivery, along with tamoxifen and tegafur\u2013gimeracil\u2013oteracil potassium. She underwent staged risk-reducing salpingo-oophorectomy and CRRM after surgery for left breast cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Even in pregnancy-associated breast cancer complicated by HBOC, management should be individualized with careful consideration of safety, and the timing of each intervention should be determined according to the specific clinical circumstances of each patient.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1847327","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:40:52Z","timestamp":1779252052000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A case of a pregnancy-associated breast cancer patient with a pathogenic variant in BRCA1 who underwent staged risk-reducing salpingo-oophorectomy and contralateral risk-reducing mastectomy"],"prefix":"10.3389","volume":"16","author":[{"given":"Haruko","family":"Takuwa","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Mitsubishi Kyoto Hospital","place":["Kyoto, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Genetics, Mitsubishi Kyoto Hospital","place":["Kyoto, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Goda","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Mitsubishi Kyoto Hospital","place":["Kyoto, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Mitsubishi Kyoto Hospital","place":["Kyoto, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/379749a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd012464.pub2","article-title":"Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations","volume":"8","author":"Eleje","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2018.09.011","article-title":"Risk reduction and survival benefit of risk-reducing salpingo-oophorectomy in hereditary breast cancer: Meta-analysis and systematic review","volume":"19","author":"Xiao","year":"2019","journal-title":"Clin Breast Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051625","article-title":"Breast cancer risk and breast-cancer-specific mortality following risk-reducing salpingo-oophorectomy in BRCA carriers: A systematic review and meta-analysis","volume":"15","author":"Gaba","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2022.02.019","article-title":"Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis","volume":"48","author":"Wang","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"B7","volume-title":"Clinical Practive Guidelines in Oncology, Breast Cancer, version 2.2026.","year":""},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2012.06.004","article-title":"Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies","volume":"38","author":"Azim","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1186\/s12885-020-07248-8","article-title":"Prognosis of pregnancy-associated breast cancer: a meta-analysis","volume":"20","author":"Shao","year":"2020","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.21610","article-title":"Breast carcinoma during pregnancy. International recommendations from an expert meeting","volume":"106","author":"Loibl","year":"2006","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.33266\/1024-6177-2023-68-1-72-77","article-title":"Pregnancy and medical radiation","volume":"30","year":"2000","journal-title":"Ann ICRP"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00299","article-title":"Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2022.03.030","article-title":"Pregnancy associated breast cancer among Israeli BRCA1\/BRCA2 carriers in a high-risk clinic","volume":"30","author":"Faermann","year":"2023","journal-title":"Acad Radiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9813253","article-title":"Metastasis of pregnancy-associated breast cancer (suspected to be hereditary breast and ovarian cancer) to the brain, diagnosed at 18 weeks\u2019 gestation: A case report and review of the literature","volume":"2016","author":"Okuda","year":"2016","journal-title":"Case Rep Obstet Gynecol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji398","article-title":"Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial","volume":"97","author":"Venturini","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.09.081","article-title":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)62048-1","article-title":"Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2\u2008\u00d7\u20082 factorial, randomised phase 3 trial","volume":"385","author":"Del Mastro","year":"2015","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22081","article-title":"Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero","volume":"107","author":"Hahn","year":"2006","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(04)01466-4","article-title":"Use of chemotherapy during human pregnancy","volume":"5","author":"Cardonick","year":"2004","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0500-0","article-title":"Outcomes of children exposed in utero to chemotherapy for breast cancer","volume":"16","author":"Murthy","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(12)70261-9","article-title":"Treatment of breast cancer during pregnancy: an observational study","volume":"13","author":"Loibl","year":"2012","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp517","article-title":"Taxanes for breast cancer during pregnancy: a systematic review","volume":"21","author":"Mir","year":"2010","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clbc.2012.09.014","article-title":"Taxanes for breast cancer during pregnancy: a systematic review","volume":"13","author":"Zagouri","year":"2013","journal-title":"Clin Breast Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/s1470-2045(20)30534-9","article-title":"Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Toi","year":"2021","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246117","article-title":"Cost-effectiveness of risk-reducing surgery for breast and ovarian cancer prevention: a systematic review","volume":"14","author":"Wei","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.0476","article-title":"Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants","volume":"8","author":"Momozawa","year":"2022","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1847327\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:41:18Z","timestamp":1779252078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1847327\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":29,"alternative-id":["10.3389\/fonc.2026.1847327"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1847327","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"article-number":"1847327"}}